Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

BACKGROUND: Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple therapy following an exacerbation of COPD is unknown. The outcomes of prompt (≤ 30 days) vs. delayed (31–180 days) initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismaila, Afisi S., Rothnie, Kieran J., Wood, Robert P., Banks, Victoria L., Camidge, Lucinda J., Czira, Alexandrosz, Compton, Chris, Sharma, Raj, Millard, Shannon N., Massey, Olivia, Halpin, David M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521462/
https://www.ncbi.nlm.nih.gov/pubmed/37749551
http://dx.doi.org/10.1186/s12931-023-02523-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521462/
https://www.ncbi.nlm.nih.gov/pubmed/37749551
http://dx.doi.org/10.1186/s12931-023-02523-1

Ejemplares similares